Imaging brain inflammation target in depression with PET
Treatments studied
Part of Mental health clinical trials.
This Phase 1 study uses a PET brain scan tracer to see how a specific brain target (PDE4B) is involved in major depressive disorder (MDD). It’s mainly testing whether the imaging approach works and what it shows in people with depression who meet specific safety and medication rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 70
- Diagnosed with major depression (no hallucinations/psychosis) for at least 4 weeks
- Recent symptom score showing moderate-to-severe depression (MADRS 18+ or HAM-D 15+ within 1 week)
- Able and willing to travel to the NIH and lie still for about 2 hours during scans
- No pregnancy; if you can become pregnant, use reliable birth control during the study
- Free of certain medicines for a set time before screening (2 weeks; longer for some specific drugs)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study uses a PET brain scan to look at inflammation-related activity (cyclooxygenase) in people with major depressive disorder (MDD). It may help researchers better understand how depression is connected to inflammation in the brain.
This trial uses two special brain scans (DPA-714 and FDG PET/MRI) to look at inflammation and brain activity in people with first-episode or recurrent depression, and in healthy volunteers. It aims to find brain differences that could lead to better treatments.
This study uses a special PET scan to look at MAO-A, a brain chemical linked to depression. It may help doctors better understand and diagnose depression.
This trial tests a personalized approach to treating major depressive disorder using assessments and brain imaging to match you with the best therapy. It aims to improve outcomes by tailoring care to your specific needs.
This study tests a special imaging agent called 11C-JMJ-129 to see how it behaves in the brain and body of healthy volunteers. The goal is to better understand a brain protein called PDE4D, which may be linked to mood and anxiety disorders.
This study uses a special PET scan to look at a brain protein called PDE4 in people with Alzheimer's disease or mild cognitive impairment. It may help researchers understand how this protein is involved in memory and thinking problems.
Hear when a new Depression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.